Craig B Langman, MD

The Isaac A Abt, MD, Professor of Kidney Diseases
Professor of Pediatrics
Feinberg School of Medicine

Head, Pediatric Kidney Diseases
Children's Memorial Research Center

Research Interests:
Dr. Craig Langman’s entire career has been devoted to the study of genetic diseases of children that produce metabolic bone disease, kidney stones, or other subtle forms of kidney disease.

He has identified patients by careful study in the areas of:
• alterations of parathyroid hormone action resulting in new diseases (latent hypoparathyroidism),
• understanding and reclassification of existing diseases (Jansen chondrodysplasia arising from an autoactivating mutation in the parathyroid hormone-parathyroid hormone like protein-receptor-1),
• a fuller understanding of the role of the kidney-localized chloride channel 5 protein (ClCN5),
• description of new concepts for hereditary hyperphosphaturia, hypophosphatemia and hypercalciuria related to intra-renal effects of IGF-1,
• and in our most recent work, still in abstract form, subtle mutations in the extracellular calcium-sensing receptor that do not produce changes in extracellular calcium, but lead to hypercalciuric stone disease.

Current Active Research Projects:
• Precursors of Osteoporosis in Children
• Proteomics of Primary Hyperoxaluria and other Genetic Stone Diseases
• Proteomics of HIV Nephropathy
• Cardiovascular Disease in Children with Chronic Kidney Disease

He has worked with colleagues around the world in order to elucidate the specific genetic defects and their meanings for patients and science alike.

Dr. Langman serves nationally as the Chair of the Scientific Advisory Board for Oxalsois and Hyperoxaluria, a genetic disease that results from mutations in a specific liver-localized enzyme; serve on the Scientific Advisory Board of the Children’s Brittle Bone Foundation, related to osteogenesis imperfecta, an inherited disease of bone related to collagen gene mutations, and on NIH panels related to kidney tubulopathies in addition to the diseases above.

Selected Publications:
Brown, W. W., Juppner, H., Langman, C. B., Price, H., Farrow, E. G., White, K. E. and McCormick, K. L. (2009). Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. J Clin Endocrinol Metab 94, 17-20.

Grujic, D., Salido, E. C., Shenoy, B. C., Langman, C. B., McGrath, M. E., Patel, R. J., Rashid, A., Mandapati, S., Jung, C. W. and Margolin, A. L. (2009). Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme in mice with hyperoxaluria. Am J Nephrol 29, 86-93.

Bobrowski, A. E. and Langman, C. B. (2008). The primary hyperoxalurias. Semin Nephrol 28, 152-62.

Brooks, E. R., Langman, C. B., Wang, S., Price, H. E., Hodges, A. L., Darling, L., Yang, A. Z. and Smith, F. A. (2008). Methylated arginine derivatives in children and adolescents with chronic kidney disease. Pediatr Nephrol.

Edwards, B. J., Langman, C. B., Bunta, A. D., Vicuna, M. and Favus, M. (2008). Secondary contributors to bone loss in osteoporosis related hip fractures. Osteoporos Int 19, 991-9.